Citius Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Citius Pharmaceuticals, Inc.
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.
Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Trail One, Inc.
- Leonard Meron Biosciences, Inc.